SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-02471

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
PRIVACY	NICARAGUA	07	Sep	2016	8	Female	24	Feb	2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Abdominal pain (Abdominal pain (10000081), Abdominal pain (10000081))
(24/Feb/2025 - 03/Mar/2025) - Recovered/Resolved
2) 8-year-old patient under treatment with the drug Eligard 22.5 mg every 3 months for Central Precocious Puberty (Off label dosing (10074165), Off label use (10053762))
(24/Feb/2025 -) - Unknown

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central precocious puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (24/Feb/2025 -)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

1)Ethylonium bromide(OTHER THERAPEUTIC PRODUCTS)

Cont..

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
debbie.maierhofer@tolmar.comand+1-4129158447

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-02471
24c. DATE RECEIVED BY MANUFACTURER: 26/May/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 05/Jun/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium via the 'ASOFARMA A TU LADO' Patient Support Program (reference number: NI-ADIUM-NI-0048-20250526) on 26-May-2025 from a consumer (non-healthcare professional) regarding a 8-year-old female child patient who experienced nonserious event of 'Abdominal pain' (Abdominal pain) and "8-year-old patient under treatment with the drug Eligard 22.5 mg every 3 months for Central Precocious Puberty" (Off label use) during Eligard (Leuprolide acetate) lyophilized for injectable suspension 22.5 milligram therapy every 3 months for indication of Central Precocious Puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 27-May-2025.

The patient's medical history and current condition were unknown.

Concomitant medication included Ethylonium bromide (coded as other therapeutic product).

On 24-Feb-2025, the patient was under treatment with drug Eligard 22.5 mg lyophilized for injectable suspension, every 3 months via subcutaneous route for Central Precocious Puberty (Lot numbers and Expiration dates were not provided) as off label use. On the same day, the patient experienced abdominal pain.

Correction treatment for abdominal pain included Otilonium bromide if required.

Action taken with Eligard in response to the events was unknown. De-challenge and re-challenge were not applicable.

3-Mar-2025, the outcome of Abdominal pain was resolved.

The outcome of event off label use was unknown.

The reporter assessed the seriousness of Abdominal pain as non-serious and did not assess the seriousness of Off label use.

The reporter did not provide the causality of Abdominal pain and Off label use in relationship to Eligard and Eligard unspecified device.

No further queries were raised.

Listedness
Abdominal pain >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Abdominal pain> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Abdominal pain> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Abdominal pain> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Off label use>Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Off label use> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Off label use> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Off label use> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This case is regarding a 8-year-old female child patient who reported Abdominal pain (Abdominal pain) and off label use (8-year-old patient under treatment with the drug Eligard 22.5 mg every 3 months for Central Precocious Puberty) during Eligard (Leuprolide acetate) 22.5 milligram therapy for central precocious puberty. Tolmar assessed the reported events as non-serious since they did not meet the ICH seriousness criteria. Considering the close temporality, the causal role of drug component of Eligard with event abdominal pain cannot be ruled out and was assessed as not related to device component. The causality of event off label use was assessed as not related to suspect Eligard(drug and device) as it is due to human action/error as per the reported information.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	:	Eligard® (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) Unknown
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month)
Route of Admin	:	1) Subcutaneous
Indications	:	1) Central precocious puberty [10073186 - Central precocious puberty]
Therapy Dates	:	1) From : 24/Feb/2025 To :Unknown

Continuation Sheet for CIOMS report

Action(s) Taken With Drug : Unknown

Causality

1) Abdominal pain (Abdominal pain - 10000081, Abdominal pain - 10000081)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) 8-year-old patient under treatment with the drug Eligard 22.5 mg every 3 months for Central Precocious Puberty (Off label dosing - 10074165, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Abdominal pain
CORE UnLabeled
2) 8-year-old patient under treatment with the drug Eligard 22.5 mg every 3 months for Central Precocious Puberty
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Central precocious puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug : Not applicable

Causality

1) Abdominal pain (Abdominal pain - 10000081, Abdominal pain - 10000081)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) 8-year-old patient under treatment with the drug Eligard 22.5 mg every 3 months for Central Precocious Puberty (Off label dosing - 10074165, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Abdominal pain
CORE
2) 8-year-old patient under treatment with the drug Eligard 22.5 mg every 3 months for Central Precocious Puberty
CORE

22.CONCOMITANT DRUG(S) (Continuation...)

1). Drug : Ethylonium bromide
Active Substance : 1) OTHER THERAPEUTIC PRODUCTS
Form Strength :
Indications : 1) Drug use for unknown indication [10057097 - Drug use for unknown indication]